A simple-to-use strategy that prevents blood clots in patients who have suffered a heart attack markedly reduces the risk of repeat heart attack or death when compared to an older, more widely used blood thinning strategy, according to a large international study presented today at the American College of Cardiology's 55th Annual Scientific Session and the inaugural Innovation in Intervention: The i2 Summit 2006 in Atlanta, Ga. ACC.06 is the premier cardiovascular medical meeting, bringing together more than 30,000 cardiologists to further breakthroughs in cardiovascular medicine. Innovation in Intervention: i2 Summit is an annual meeting for practicing cardiovascular interventionalists sponsored by the American College of Cardiology in partnership with the Society for Cardiovascular Angiography and Interventions.
The ExTRACT-TIMI 25 trial compared a strategy using enoxaparin, a type of low-molecular-weight heparin, to a strategy using unfractionated heparin as adjunctive therapy in patients whose primary treatment for heart attack, or myocardial infarction (MI), was clot-busting medication, known as fibrinolytic drugs. Both unfractionated heparin and enoxaparin inhibit thrombin, a blood protein that plays a key role in the formation of new blood clots. However, unfractionated heparin is delivered by intravenous infusion, while enoxaparin can simply be injected under the skin. Enoxaparin also appears to have more powerful anti-clotting effects by more effectively blocking the clotting mechanism at an earlier stage than unfractionated heparin.
"Our study provides compelling evidence that the enoxaparin strategy is superior to the standard unfractionated heparin strategy as antithrombin therapy to support fibrinolytic therapy," said Dr. Elliott Antman, M.D., a professor of medicine at Harvard Medical School, Boston, and the Principal Investigator of the Enoxaprin and Thrombosis Reperfusion for Acute Myocardial Infarction Treatment: Thrombosis in MyoPage: 1 2 3 Related medicine news :1
. US beats Europe for hypertension treatment2
. For super-obese patients, duodenal switch beats gastric bypass3
. Efficacy and safety of Aripiprazole as adjunctive therapy in major depressive disorder4
. New data demonstrate effectiveness of LAMICTAL (lamotrigine) as adjunctive therapy5
. Chemotherapy with bevacizumab increases risk of blood clots in arteries6
. Nonsmall cell lung cancer -- chemotherapy before surgery appears better than surgery alone7
. Stroke in nonvascular atrial fibrillation -- anti-coagulants better than anti-platelet therapy8
. Hormone therapy offers new hope for ovarian cancer patients9
. Borderline personality disorder shows improvements with intensive psychotherapy10
. Trial shows circulating tumor cells predict how prostate cancer patients do with chemotherapy11
. Chemotherapy may enhance the effectiveness of brain tumor vaccines